Jan 5 (Reuters) - U.S. pharma giant Pfizer Inc is planning to pull back on early-stage research into treatments for rare diseases, including development of new viral-based gene therapies, financial newspaper Barron's said on Thursday. (Reporting by Shubhendu Deshmukh in Bengaluru; Editing by Sherry Jacob-Phillips)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.03 USD | +1.80% | +5.93% | +4.31% |
12:04am | OPKO Health Raises $250 Million Non-Dillutive Capital Via Note Issue | MT |
17/07 | Mark Cuban's Cost Plus to import penicillin to address US shortage | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.31% | 167B | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+2.52% | 125B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Pfizer plans to pull back on early-stage rare disease research - Barron's